Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.59 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.59 |
| ▸ | PARP1 | P09874 | 5/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 6/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432009 | 0.87 | PARP10 (0.63) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1727568 | 0.83 | PARP10 (0.58) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL793156 | 0.81 | PARP10 (0.77) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1726500 | 0.81 | PARP10 (0.55) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL30549705 | 0.79 | PARP10 (0.68) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL25928045 | 0.78 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1726570 | 0.77 | PARP10 (0.48) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL18199142 | 0.77 | CNR1 (0.48) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL18936968 | 0.75 | MAPK1 (0.46) | PARP10PARP11 | |
| SCHEMBL1417646 | 0.75 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403846-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| EP-2729466-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013008095-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2403846-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100070-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | BTK, LCK, ZAP70 | PARP10 774/4885PARP11 883/4885PARP1 1109/4885 |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | PARP10 1163/4885PARP11 971/4885PARP1 1615/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | PARP10 1286/4885PARP11 960/4885PARP1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.